The Comparison of Tacrolimus and Sirolimus Immunosuppression Based Drug Regimens in Kidney Transplant Recipients
Kidney Diseases
About this trial
This is an interventional treatment trial for Kidney Diseases focused on measuring kidney transplantation, immunosuppression, calcineurin inhibitor, sirolimus, chronic allograft nephropathy
Eligibility Criteria
Inclusion Criteria: Living and deceased donor kidney transplant recipients at the Mayo Clinic, Rochester, Minnesota Exclusion Criteria: Patients with type 1 diabetes less than 50 years of age who receive a living donor kidney transplant followed by a pancreas transplant Pediatric patients (<18 years of age) Multi-organ transplants (e.g., kidney-pancreas, kidney-liver) ABO-incompatible or positive crossmatch recipients (ABO incompatibility is an immune system reaction that occurs when blood from two different and incompatible blood types are mixed together.) Patients with severe hyperlipidemia (serum cholesterol >350 mg/dl or serum triglycerides >500 mg/dl Patients with severe leukopenia (White Blood Cell count [WBC]<3000 10^3/ml) Patients unwilling to return to the transplant center for late follow-up visits Body mass index (BMI) ≥ 32 with incisional problems post transplant (as determined by renal transplant surgeon
Sites / Locations
- Mayo Clinic
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Tacrolimus
Sirolimus
Calcineurin inhibitor arm, consisting of treatment with tacrolimus, mycophenolate mofetil, and prednisone.
Calcineurin inhibitor-free arm, consisting of treatment with rapamycin, mycophenolate mofetil, and prednisone.